Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Ipsen

Tracked across 8 events · 62 articles · First seen Apr 20, 2026 · Last active Sep 22, 2026

Sentiment
21
Attention
6
Events
8
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 70
Business
Impact: Ipsen is acquiring Kartos Therapeutics, expanding its oncology pipeline with navtemadlin, a late-stage rare blood cancer asset. This acquisition is expected to contribute to Ipsen's core operating income from 2029.
Apr 20, 2026 · 7 articles
3 50
Business
Impact: Ipsen completed the acquisition of Memo Therapeutics, adding potravitug to its rare disease pipeline, which may drive future revenue growth.
Jul 01, 2026 · 16 articles
1 10
Business
Impact: Ipsen appointed Catherine Ashmore Bradley as an independent director, strengthening its board with financial expertise.
Jul 29, 2026 · 7 articles
4 60
Business
Impact: Ipsen completed the acquisition, adding a promising late-stage asset to its pipeline. The deal strengthens its oncology franchise and may drive future revenue growth.
Aug 21, 2026 · 7 articles
0 0
Business
Ipsen, a French biopharmaceutical company listed on Euronext Paris Paris (IPN) and through a US ADR program (IPSEY), announced on 18 September 2026 the co-optation of Mariette Finet as a Director to its Board of…
Impact: Ipsen is the company making the board appointment; the change is a routine governance matter with no expected material effect on its operations or valuation.
Sep 18, 2026 · 7 articles
2 5
Regulatory
Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry.…
Impact: One of the nine drugmakers signing the letter calling for greater EU investment in the sector. The initiative reflects its interest in a more competitive European pharmaceutical environment.
Sep 22, 2026 · 6 articles
2 -30
Regulatory
Amneal Pharmaceuticals received U.S. United States — Food and Drug Administration approval for its lanreotide injection, 120 mg/0.5 mL, a generic version of Somatuline Depot, and launched the product immediately. The approval carries Competitive Generic…
Impact: Ipsen's branded Somatuline Depot, with $983 million in U.S. annual sales, now faces generic competition from Amneal's approved lanreotide injection.
Sep 18, 2026 · 6 articles
1 0
Business
Impact: Ipsen is mentioned as Jenkins' former employer; no direct impact from this event.
Jul 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Ipsen live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.